ArticleInternational journal of oncology2016
Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer.
Article in International journal of oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Contemporary Precision Stratification and Prognostic Features of Primary Gliomas in a Southern Chinese Population.Research (Washington, D.C.) · 2025Article
- Genomic and Transcriptomic Analysis of Neuroendocrine Transformation inJTO clinical and research reports · 2022Article
- Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.Frontiers in genetics · 2022Article
- Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation.Cancer discovery · 2021Article
- Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations.Computational and structural biotechnology journal · 2021Article
- Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Analysis of Cross-Association between mRNA Expression and RNAi Efficacy for Predictive Target Discovery in Colon Cancers.Cancers · 2020Article
- Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital.Oncology letters · 2019Article
- Synthetic Lethality in Lung Cancer-From the Perspective of Cancer Genomics.Medicines (Basel, Switzerland) · 2019Review
- Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.Protein science : a publication of the Protein Society · 2017Article
- Article
- Synthetic lethality in lung cancer and translation to clinical therapies.Molecular cancer · 2016Review
- Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Genetic alterations in lung cancer are distinctly represented in non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Mutation of the RB1 and CDKN2A genes, which are tightly associated with cell cycle regulation, is exclusive to SCLC and NSCLC cells, respectively. Through the systematic analysis of transcriptome and proteome datasets for 318 cancer cell lines, we characterized differential gene expression and protein regulation in RB1-mutant SCLC and CDKN2A-mutant NSCLC. Many of the genes and proteins associated with RB1-mutant SCLC cell lines belong to functional categories of gene expression and transcription, whereas those associated with CDKN2A-mutant NSCLC cell lines were enriched in gene sets of the extracellular matrix and focal adhesion. These results indicate that the loss of RB1 and CDKN2A function induces distinctively different signaling cascades in SCLC and NSCLC cells. In addition, knockdown of the RB1 gene in CKDN2A-mutant cell lines (and vice versa) synergistically inhibits cancer cell proliferation. The present study on the exclusive role of RB1 and CDKN2A mutations in lung cancer subtypes demonstrates a synthetic lethal strategy for cancer regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.